Your browser doesn't support javascript.
loading
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Tye-Din, Jason A; Daveson, A James M; Goel, Gautam; Goldstein, Kaela E; Hand, Holly L; Neff, Kristin M; Popp, Alina; Taavela, Juha; Maki, Markku; Isola, Jorma; Williams, Leslie J; Truitt, Kenneth E; Anderson, Robert P.
Afiliação
  • Tye-Din JA; Immunology Division, The Walter and Eliza Hall Institute, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia; Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Centre for Food & Allergy Research, Inf
  • Daveson AJM; Greater Brisbane Clinical School, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Wesley Medical Research, Auchenflower, QLD, Australia; Coral Sea Clinical Research Institute, North Mackay, Queensland, Australia.
  • Goel G; ImmusanT, Cambridge, Massachusetts, USA.
  • Goldstein KE; ImmusanT, Cambridge, Massachusetts, USA.
  • Hand HL; ImmusanT, Cambridge, Massachusetts, USA.
  • Neff KM; ImmusanT, Cambridge, Massachusetts, USA.
  • Popp A; University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland.
  • Taavela J; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland.
  • Maki M; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Tampere, Finland.
  • Isola J; Department of Clinical Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Jilab, Tampere, Finland.
  • Williams LJ; ImmusanT, Cambridge, Massachusetts, USA.
  • Truitt KE; ImmusanT, Cambridge, Massachusetts, USA.
  • Anderson RP; ImmusanT, Cambridge, Massachusetts, USA. Electronic address: robert.anderson2@health.qld.gov.au.
Lancet Gastroenterol Hepatol ; 8(5): 446-457, 2023 05.
Article em En | MEDLINE | ID: mdl-36898393
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Celíaca Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Celíaca Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article